

In association with



Promoted by

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINAMADORI



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Unità Sanitaria Locale della Romagna

3 soho Italy

2021 ANNUAL CONFERENCE HYBRID EVENT

Rome - Italy

27 - 28 - 29 - 30 Sept. 2021

A. Roma Lifestyle Hotel

www.sohoitaly.it

JOIN US!

Free registration
www.sohoitaly.it

Organizing secretariat



www.proeventi.it
info@proeventi.it

Follow us

#SOHOItaly2021





Patronage



ALLEANZA
CONTRO
IL CANCRO



Associazione Italiana di Oncologia Medica



ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE,
LINFOMI E MIELOMA



FONDAZIONE
ITALIANA
LINFOMI



GRUPPO ITALIANO PER IL TRATTAMENTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMPOIETICHE E TERAPIA CELLULARE



istituto
oncologico
romagnolo
vicino a chi soffre,
insieme a chi cura



Ordine
Nazionale
Biologi

SIE
Società Italiana
di Ematologia



SIES



SOCIETÀ ITALIANA DI FARMACOLOGIA



TUMORE AL SENO METASTATICO
noicisiamo

In Association with



society of hematologic oncology

Promoted by

ISTITUT
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINAMADORI



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Azienda Unità Sanitaria Locale della Romagna



Day 1

28
09.21

Day 2


29
09.21

Day 3

30
09.21

SUMMARY

| | |
|------------------------|----|
| With the Patronage | 1 |
| Summary | 3 |
| About SOHO Italy | 4 |
| Presidents | 6 |
| Scientific Board | 7 |
| Scientific Secretariat | 11 |
| Key Information | 12 |
| General Information | 13 |
| Public Transport | 14 |
| Program Table | 15 |
| Day 0 (Virtual Only) | 20 |
| Day 1 | 29 |
| Day 2 | 36 |
| Day 3 | 41 |
| Follow Us! | 48 |



What is SOHO Italy?

The Italian Society of Hematologic Oncology is bringing together leading SOHO experts and top Italian researchers in acute leukemias, MPDs and MDSs, aims to consolidate the Italian Hematology-SOHO partnership.

Purpose

The aim of the association is the integration of the clinical-scientific activities of IRST Meldola and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.

Represented by

The Society SOHO Italy is represented by G. Martinelli and C. Cerchione, IRST Meldola, and H. Kantarjian, E. Jabbour, M. Konopleva, N. Daver, MD Anderson Cancer Center.




PRESIDENTS

Claudio Cerchione



Since 2018, he works in Hematology Unit of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS. He also has spent international research experiences in Friedrich-wilhelms universität, Bonn, Germany, in Universidade de Coimbra, Portugal, collaborating in their clinical and research projects, and in MD Anderson Cancer Center, Houston, USA, where he was nominated Ambassador of SOHO (Society of Hematologic Oncology). He is member of the editorial boards of many scientific journals, and member of several international societies, including the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH), European Hematology Association (EHA) and Italian Society of Hematology (SIE).

Hagop Kantarjian



Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003 - present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics.

Giovanni Martinelli



As of 1 January 2018, Professor Giovanni Martinelli is scientific director of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Dino Amadori (IRST) IRCCS, in Meldola (FC), Italy. Until December 2017, Professor Giovanni Martinelli was associate professor of Hematology at the Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliera S. Orsola - Malpighi at the University of Bologna, Italy. His main fields of research are AML, ALL and CML, including research on targeted therapies in major hematological syndromes: Acute Leukemias, CML (both Philadelphia-chromosome positive and non - positive), and hypereosinophilic syndrome.



Scientific Board

Claudio Cerchione

Hagop Kantarjian

Giovanni Martinelli

Naval G. Daver



“Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He is a clinical investigator with a focus on molecular and immune therapies in AML and myeloid disease and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AML and is leading a number of these trials at MDACC. Dr Daver has published >240 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals.”

Courtney DiNardo



Dr. DiNardo interests are focused on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014.

The HHMC provides research based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials. My expertise in myeloid malignancy metabolomics has also driven my research related to therapeutic targeting of glutamine metabolism in myelodysplastic syndrome.



Alessandra Ferrajoli



Dr. Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields Dr. Ferrajoli has authored and co-authored more than two hundred and fifty publications in peer reviewed journals. She serves on numerous journal editorial boards and grant proposal study sessions for several US and European Agencies.

Nathan H. Fowler



His interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where he helped to develop some of the first protocols to use lenalidomide in CLL. Since joining the faculty at MD Anderson Cancer Center, the goal of his clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma. He serves as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.

Guillermo Garcia-Manero



Guillermo Garcia-Manero, M.D., is a physician-scientist specializing in state-of-the-art treatments for leukemia. His research focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and his goal is develop and validate new therapeutics to treat these deadly diseases. He leads teams of clinicians, medical fellows, nurses, physician assistants and researchers to conduct pre-clinical, translational, and clinical studies. The goal of these studies is to understand, treat, and eventually cure MDS, AML and other leukemias.



Elias Jabbour



Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; 5) triple therapy in AML.

Hans C. Lee



Hans C. Lee, MD, is an Assistant Professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas where he focuses his efforts on the clinical care and research of patients with plasma cell dyscrasias. He has a particular interest and focus on early phase clinical trials and novel therapeutic approaches to relapsed and/or refractory multiple myeloma.


Tapan M. Kadia



Dr. Tapan Kadia is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these.



Marina Konopleva



Dr. Konopleva is a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. Her laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs. She has also been an active mentor to trainees including undergraduate, medical and graduate students, post-doctoral fellows who have trained under her direction in support of her various laboratory grants and projects.

Gerardo Musuraca



Dr. Musuraca is the Chief of Hematology Unit at IRST – IRCCS, in Meldola (FC), Italy. After a degree cum laude at the University of Bologna and a specialization in Hematology, since January 2006 he has been a PhD student in Clinical and Experimental Hematology at the University of Bologna. In 2007 he began the Clinical activity and research at Cancer Institute of Romagna. He is also Abstracts Reviewer and moderator on lymphoma, preclinical and biological agents of the American Society of Hematology meeting (ASH) and in December 2011 he reached a highly specialized position on Lymphomas at the Cancer Institute of Romagna. Dr. Musuraca is Coauthor of more than 43 publications and Since 2001 he is involved in more than 200 multicenter national and international clinical trials performed in onco-hematology (Lymphomas), according to the FDA regulations and/or ICH-GCP guidelines.

Farhad Ravandi-Kashani



Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.



Srdan Verstovsek



Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at MD Anderson, he is a global leader in myeloproliferative neoplasms (MPN) and the Founder/ Director of the largest MPN Clinical Research Center worldwide. He has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He is leading pivotal phase 3 trials for several promising myelofibrosis medications. Dr. Verstovsek received several distinguished awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research (2017) and the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013). He was elected member of The American Society for Clinical Investigation (2015) and received the Celgene 2010 Young Investigator Award for Clinical Research.

Scientific Secretariat

Claudio Cerchione
Giovanni Martinelli
Gerardo Musuraca





Key Information

VENUE

A. ROMA LIFESTYLE HOTEL

Via Giorgio Zoega, 59, 00164 Roma, Italy

MEETING

Monday, Sept. 27

08.30 - 19.45

Tuesday, Sept. 28

08.30 - 19.00

Wednesday, Sept. 29

07.45 - 20.30

Thursday, Sept. 30

07.45 - 20.00

SOCIAL MEDIA

Soho Italy is active on various social media platform. Follow us on the networks below and get real-time updates:



Facebook: Soho Italy



Twitter: @sohoitaly



Linkedin: Soho Italy



Instagram: sohoitaly

#SOHOItaly2021

INTERNET

WiFi is available in all areas.





General Information

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 16–27 degrees.

BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

TAXI

The single number to call a taxi is 060609, for other utilities on the taxi service, see www.060608.it.

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€

The rates from Termini railway station to the city centre should cost between € 8 and € 15.





Public Transport



The hotel is a 9-minute walk from the Baldo degli Ubaldi stop, Line A towards Battistini.





Program Table

Monday
Sept. 27

08.00

09.00


09.40 - 09.55 Opening Session

10.00

09.55 - 10.25 Systemic Mastocytosis

10.25 - 11.40

11.00

 **Satellite Symposium: Artificial Intelligence applications in oncohematology**

12.00



11.40 - 13.40

13.00

 **Lunch Satellite Symposium: Exploiting Cell T for Graft versus Malignancy and GVHD**

14.00

13.40 - 14.40

 **Symposium**  **Jazz Pharmaceuticals**
Targeted therapy in HR-AML

15.00

14.40 - 15.55

 **Satellite Symposium:**
From skin lesions to a rare hematological malignancy

16.00

15.55 - 18.00

17.00

  **CAR-T Symposium**

18.00

18.00 - 19.30

  **Satellite Symposium - Medical Crossfire® Practical Considerations for Integrations of Biosimilars into Patient Care Pathways for Hematologic Malignancies**

19.00

20.00

19.30 - 21.00

  **Dinner Symposium:**
Optimizing Use of T-Cell Engaging Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia

21.00



Program Table

Tuesday
Sept. 28

08.00

08.30 - 09.30

09.00

Opening Session

09.30 - 10.15

10.00

Biology of Acute Myeloid Leukemia

10.30 - 11.30

11.00

Acute Myeloid Leukemia Clinical Session 1

11.30 - 12.45


12.00

Acute Myeloid Leukemia Clinical Session 2

12.45 - 15.30

13.00

14.00

Lunch Symposium:  - CSH
(Chinese Society of Hematology)

15.00

15.30 - 18.15

16.00

17.00

 Acute Myeloid Leukemia

18.00


18.30 - 19.30

19.00

Acute Myeloid Leukemia Clinical Session 3

19.30 - 20.30

20.00

 Myelodysplastic Syndromes Symposium

21.00

20.30 - 21.00

Acute Lymphoblastic Leukemia – Biology



Wednesday
Sept. 29

08.00

08.30 - 09.45

09.00

Non Hodgkin Lymphoma – DLBCL

10.00

09.45 - 10.45

Non Hodgkin Aggressive Lymphoma – Clinical Session

11.00

11.00 - 12.20

Hodgkin Lymphoma, Non Hodgkin Indolent Lymphomas and Waldenstrom
Disease - Clinical Session

12.00

12.20 - 13.20

13.00

Chronic Lymphocytic Leukemia – Clinical Session

14.00

13.50 - 15.20

15.00



Lymphomas and Chronic Lymphocytic Leukemia Symposium

16.00

15.20 - 16.35

Chronic Myeloid Leukemia – Clinical Session

17.00

16.50 - 18.20



CML and Myeloproliferative Neoplasms
Symposium

18.00

18.20 - 20.05

19.00



Acute Lymphoblastic Leukemia Symposium

20.00

21.00



Thursday
Sept. 30

08.00

08.30 - 09.30

09.00

Selected Oral Presentations

10.00

09.30 - 11.00

Multiple Myeloma - Biology

11.00

11.00 - 12.15

12.00

Multiple Myeloma – Clinical Session 1

13.00

12.30 - 13.45

Multiple Myeloma – Clinical Session 2

14.00

14.05 - 15.35



Health Management System

15.00

15.35 - 17.20

16.00



Multiple Myeloma Symposium

17.00

17.20 - 18.50

18.00

Acute Lymphoblastic Leukemia – Clinical Session

19.00

19.05 - 20.05

20.00

Chronic Myeloproliferative Neoplasms –
Session on novel targets

21.00



Day 0

27

09·21

**VIRTUAL ONLY
EXTRA CME DAY**



Opening Session

Ita 09.40 - 09.55 Tx 02.40 - 02.55 AM

Chairs: C. Cerchione, G. Martinelli

09.40 - 09.55

Introduction and Welcome to Satellite Symposia Day - Day 0

C. Cerchione, G. Martinelli

Satellite Symposium: Systemic Mastocytosis

Ita 09.55 - 10.25 Tx 02.55 - 03.25 AM

Chairs: C. Papayannidis, A. Romano



09.55 - 10.10

Systemic Mastocytosis: Diagnosis and Classification

A. Romano

10.10 - 10.25

How I treat Systemic Mastocytosis in 2021

C. Papayannidis



Satellite Symposium: Artificial Intelligence applications in oncohematology

Ita 10.25 - 11.40 Tx 03.25 - 05.40 AM

Chairs: C. Cerchione, G. Martinelli, A. Mosquera



10.25 - 10.35

Presentation and introduction to the session

C. Cerchione, G. Martinelli, A. Mosquera

10.35 - 10.45

Introduction to Machine Learning in Hematology

A. Mosquera

10.45 - 10.55

New Perspectives of big data in Patient-Related Outcome Measurements (PROMs)

R. Córdoba Mascuñano

10.55 - 11.05

MM prognostication and optimal drug selection

M. S. Gonzalez

11.05 - 11.20

Hot topics in the treatment of MM where clinical trials may not suffice

M. Mateos

11.20 - 11.30

Identification of CLL patients at high risk of infection using AI

C. Niemann

11.30 - 11.40

Machine learning in hematology: what to expect in the future

A. Mosquera

Closing remarks

C. Cerchione, G. Martinelli, A. Mosquera

Satellite Symposium: Exploiting Cell T for Graft versus Malignancy and GVHD

Ita 11.40 - 13.40 Tx 05.40 - 06.40 AM

Chairs: C. Cerchione, G. Martinelli, A. Olivieri



A. Exploiting CELL T for Graft versus Malignancy

Chairs: A. Olivieri, P. L. Zinzani

Introduction A. Olivieri

11.40 - 11.55

DLI: do they still play a role?

F. Saraceni

11.55 - 12.10

CAR-T in Non-Hodgkin Lymphoma: long term outcome and updated safety profile in the real life scenario

P. L. Zinzani

12.10 - 12.25

CAR-T in MM: preliminary data and perspectives

C. Cerchione

12.25 - 12.40

NK in AML

A. Curti

12.40 - 12.55

CIK in Acute Leukemia

F. Lussana

B. Exploiting CELL T for GVHD management

Chairs: C. Cerchione and G. Martinelli

12.55 - 13.10

T- REG

M. Di Ianni

13.10 - 13.25

MSC

M. Introna

Closing remarks

C. Cerchione, G. Martinelli, A. Olivieri



Jazz Pharmaceuticals®

Symposium Jazz Pharmaceuticals: Targeted therapy in HR-AML

Ita 13.40 - 14.40 Tx 06.40 - 07.40 AM

Chairs: C. Cerchione, G. Martinelli



13.40 - 14.05

Intensive chemotherapy matters: who is the eligible patient?

F. Buccisano

14.05 - 14.30

RWE matters: intensive chemotherapy in HR-AML

F. Guolo

14.30 - 14.40

Open discussion



A Menarini Group Company

STEMLINE A menarini group company Satellite Symposium: From skin lesions to a rare hematological malignancy

Ita 14.40 - 15.55 Tx 07.40 - 08.55 AM

Chairs: C. Cerchione , G. Martinelli

14.40 - 14.45

Opening

Chairs: C. Cerchione, G. Martinelli

14.45 - 14.55

The gift of time for patients who can't wait: skin lesions catalyzing the early detection of very aggressive hematologic malignancies

C. Massone

14.55 - 15.05

Biomarkers unwinding the diagnostic path

W. M. Stadler

15.05 - 15.15

Taking the torch from discoverers: bring forth hope to hopeless patients with devastating neoplasms such as BPDCN

N. Pemmaraju

15.15 - 15.40

Selection of real cases

- **Patient perspective** Chairpersons
- **Case presentations** B. Papoular, G. Rivoli
- **Need for registries** G. Marconi

15.40 - 15.50

Round table & Q&A: consolidation and future perspectives for BPDCN

C. Cerchione, G. Martinelli

Closing Remarks

C. Cerchione, G. Martinelli



CAR-T Symposium

Ita 15.55 - 17.55 Tx 08.55 - 10.55 AM

Chairs: C. Cerchione, F. Locatelli, G. Martinelli, J. Nitin



15.55 - 16.10

T-cell and NK-cell based therapies in AML

N. Daver

16.10 - 16.25

CAR-T for Pediatric ALL: What's Next?

F. Locatelli

16.25 - 16.40

Allogeneic CAR-T cell therapy and MDACC CARTOX program

J. Nitin

16.40 - 16.55

From the development of CAR-T to Hospital Exemption approval in an academic hospital

M. Juan

16.55 - 17.10

Overcoming Challenges in CAR-T cell

C. Quintarelli

17.10 - 17.25

CAR-T in solid tumors

M. Dominici

17.25 - 17.40

CAR-T activities and vision in the context of Alliance Against Cancer

M. Mazza

17.40 - 17.55

T-cell and NK-cell based therapies in AML

N. Daver

17.55 - 18.00

Discussion



PER/SOHO Italy Satellite Symposium

Ita 18.00 - 19.30 Tx 11.00 AM - 00.30 PM

Chairs: N. Daver

PANEL DISCUSSION ABOUT

Medical Crossfire® Practical Considerations for Integrations of Biosimilars into Patient Care Pathways for Hematologic Malignancies

18.00 - 18.05

Welcome and Introductions

N. Daver

18.05 - 18.25

Regulatory Considerations in Oncology Biosimilars

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

18.25 - 18.40

Understanding Best Practices in the Manufacture of Biosimilars

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

18.40 - 19.00

The Role of Biosimilars in Management of Hematologic Malignancies: Efficacy and Safety Considerations

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

19.00 - 19.20

Shared Decision-Making: Navigating Common Barriers

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

19.20 - 19.30

Audience Q&A

C. Cerchione, N. Daver, E. Jabbour, H. Kantarjian, G. Martinelli

19.30

Conclusion

N. Daver

Accreditation/Credit Designation

For information about EACCME and ACCME credit go to: <https://www.gotoper.com/go/italy21hem-wc>

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.



PER/SOHO ITALY Dinner Symposium: Optimizing Use of T-Cell Engaging Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia

Ita 19.30 - 21.00 Tx 00.30 - 02.00 PM

Chairs: E. Jabbour

soho
italy
society of hematologic oncology

PER
Physicians' Education Resources, LLC

19.30 - 19.35

Welcome and Introductions

E. Jabbour

19.35 - 19.45

Understanding the Pathophysiology of ALL and Establishing a Diagnosis

H. Kantarjian

19.45 - 20.05

Frontline Treatment Decisions in ALL

E. Jabbour

20.05 - 20.25

Leveraging Minimal Residual Disease in ALL Treatment Planning and Prognosis

J. M. Ribera

20.25 - 20.45

Updates in Relapsed/Refractory ALL Management

G. Martinelli

20.45 - 21.00

Audience Q&A

E. Jabbour, H. Kantarjian, G. Martinelli, J. María Ribera

21.00

Conclusion

E. Jabbour

Accreditation/Credit Designation

For information about EACCME and ACCME credit go to: <https://www.gotoper.com/go/italy21all-wc>


Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Day 1

28

09·21



Opening Session

Ita 08.30 - 09.30 Tx 01.30 - 02.30 AM

Chairs: C. Cerchione, F. Locatelli, G. Martinelli

00
Session

08.30 - 08.45

What is SOHO Italy and next steps

C. Cerchione, G. Martinelli

08.45 - 09.00

How I manage hematologic malignancies during the COVID-19 pandemic

F. Locatelli

09.00 - 09.15

Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy

F. Passamonti

09.15 - 09.30

Italian researchers and COVID-19 pandemic: what we have learnt in these years

G. Martinelli

Biology of Acute Myeloid Leukemia

Ita 09.30 - 10.15 Tx 02.30 - 03.15 AM

Chairs: S. Galimberti, G. Simonetti

01
Session

09.30 - 09.45

Toward new horizons in biology of Acute Myeloid Leukemia

G. Simonetti

10.00 - 10.15

Proapoptotic pathways in AML

S. Galimberti

09.45 - 10.00

New insights in synthetic lethality in AML

A. Ghelli

10.15 - 10.30 Coffee Break

Acute Myeloid Leukemia Clinical Session 1

Ita 10.30 - 11.30 Tx 03.30 - 04.30 AM

Chairs: B. Falini, G. Visani

02
Session

10.30 - 10.45

How I treat elderly AML in Europe

F. Ferrara

10.45 - 11.00

Elderly AML: room for improvement

A. Isidori

11.00 - 11.15

Management of BPDCN in Italy

E. Angelucci

11.15 - 11.30

How I diagnose and treat

NPM1-mutated AML

B. Falini

Acute Myeloid Leukemia Clinical Session 2

Ita 11.30 - 12.45 Tx 04.30 - 05.45 AM

Chairs: C. Mecucci, A. Olivieri

03
Session

11.30 - 11.45

IDH1/IDH2 inhibition in Acute Myeloid Leukemia

M.P. Martelli

11.45 - 12.00

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

L. Brunetti

12.00 - 12.15

Role of ASCT in AML in the era of novel agents

A. Olivieri

12.15 - 12.30

Immunotherapy and monoclonal antibodies in AML in Europe

A. Candoni

12.30 - 12.45

Modeling and targeting of erythroleukemia by hematopoietic genome editing

I. Iacobucci



Lunch Symposium: SOHO Italy-CSH (Chinese Society of Hematology)

Ita 12.45 - 15.30 Tx 05.45 - 08.30 AM

Chairs: C. Cerchione, G. Martinelli, D. Wu

Session 1: Myeloma

12.45 - 12.55

Welcome Speech

C. Cerchione, G. Martinelli, D. Wu

12.55 - 13.05

How I treat relapsed/refractory
Multiple Myeloma in China

C. Fu

13.05 - 13.15

How I treat relapsed/refractory
Multiple Myeloma in Europe

C. Cerchione

13.15 - 13.25

How I treat relapsed/refractory
Multiple Myeloma in America

K. Anderson

13.25 - 13.30

Panel Discussion – ALL

Session 2: Lymphoma

13.30 - 13.40

ASCT or CAR-T in DLBCL

C. Qu

13.40 - 13.50

Genetic Profiling and Biomarkers in
nodal Peripheral T-cell Lymphomas:
Current Role in the Diagnostic
Work-up

F. Vega

13.50 - 14.00

How I manage DLBCL

N. Fowler

14.00 - 14.05

Panel Discussion - ALL

Session 3: Leukemia

14.05 - 14.15

Current treatment of acute myeloid leukemia in China

J. Wang

14.15 - 14.25

Acute Promyelocytic leukemia with variant retinoid acid receptor fusions

S. Chen

14.25 - 14.35

Emerging targeted therapies and combinations for AML

N. Daver

14.35 - 14.45

Immune based and novel therapies in AML

N. Daver

14.45 - 14.55

Near future of FLT3 inhibitors in AML

G. Martinelli

14.55 - 15.05

How I manage Ph-positive Acute Lymphoblastic Leukemia at MDACC

E. Jabbour

15.05 - 15.15

How I manage elderly Acute Lymphoblastic Leukemia

E. Jabbour

15.15 - 15.25

Near future of AML and ALL therapies

H. Kantarjian

15.25 - 15.30

Panel Discussion – ALL

Closing

C. Cerchione, G. Martinelli, D. Wu



Acute Myeloid Leukemia

Ita 15.30 - 18.15 Tx 08.30 - 11.15 AM

Chairs: C. Cerchione, N. Daver, C. DiNardo, T. Kadia, H. Kantarjian,
G. Martinelli, F. Ravandi



Extra

CME SESSION

15.30 - 15.45

AML research and therapy in 2021

H. Kantarjian

15.45 - 16.00

Novel Strategies to Treat Elderly with AML

T. M. Kadia

16.00 - 16.15

Maintenance Therapy in AML: new perspectives

F. Ravandi

16.15 - 16.30

IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy

C. DiNardo

16.30 - 16.45

Immunotherapy and TP53 Mutated AML: New Horizons

N. Daver

16.45 - 17.00

FLT3 mutated AML: Moving Towards Cure

G. Martinelli

17.00 - 17.15

Mechanisms of resistance to FLT3 inhibitors and novel combinations in FLT3m AML

N. Daver

17.15 - 17.30

TP53 in Myeloid Leukemias : Targeting the Guardian of the Genome

M. Andreeff

17.30 - 17.45

How I manage BPDCN in MDACC

N. Pemmaraju

17.45 - 18.00

New frontiers in overcoming Environment-Mediated Drug Resistance in AML

C. Cerchione

18.00 - 18.15

What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms

M.T. Voso

18.15 - 18.30 Coffee Break

Acute Myeloid Leukemia Clinical Session 3

Ita 18.30 - 19.30 Tx 11.30 AM - 00.30 AM

Chairs: A. De La Fuente, G. Martinelli

04
Session

18.30 - 18.45

CPX-351 in secondary AML

A. Curti

18.45 - 19.00

Role of postSCT maintenance in AML

M. Gottardi

19.00 - 19.15

New insights on MRD Assessment by Flow Cytometry in AML

F. Buccisano

19.15 - 19.30

Novel agents in the management of AML: Phase 4 trials in Spain

A. De La Fuente

Myelodysplastic Syndromes Symposium

Ita 19.30 - 20.30 Tx 00.30 - 01.30 PM

Chairs: C. Cerchione, G. Garcia Manero, G. Martinelli, V. Santini

soho
society of hematologic oncology
Extra
CME SESSION

19.30 - 19.45

A Primer on the Biology of MDS

S. Colla

19.45 - 20.00

Management of MDS in Europe

V. Santini

20.00 - 20.15

Management of MDS in MDACC

G. Garcia-Manero

20.15 - 20.30

Update on CMML

G. Montalban-Bravo

Acute Lymphoblastic Leukemia – Biology

Ita 20.30 - 21.00 Tx 01.30 - 02.00 PM

Chairs: A. Ferrari, J. Ribera

05
Session

20.30 - 20.45

Triple negative ALL – past, present and future

A. Ferrari

20.45 - 21.00

Role of MRD in ALL

J. Ribera

Closing remarks Day 1

Ita 21.00 Tx 02.00 PM

Chairs: C. Cerchione, G. Martinelli

soho
society of hematologic oncology

Day 2

29

09.21

Non Hodgkin Lymphoma – DLBCL

Ita 08.30 - 09.45 Tx 01.30 - 02.45 AM

Chairs: E. Derenzini, G. Musuraca, S. Pileri M. Spina

06
Session

08.30 - 08.45

**How I treat Diffuse Large B-Cell
Lymphoma in Europe**

G. Musuraca

08.45 - 09.00

**New insights into the management of
Relapsed/Refractory DLBCL**

E. Derenzini

09.00 - 09.15

DLBCL: Lesson from Machine learning

A. Mosquera

09.15 - 09.30

**Predictive and Prognostic Molecular
Factors in Diffuse Large B-Cell
Lymphomas**

S. Pileri

09.30 - 09.45

**Geriatric score and the treatment of
elderly patients with DLBCL**

M. Spina

Non Hodgkin Aggressive Lymphoma Clinical Session

Ita 09.45 - 10.45 Tx 02.45 - 03.45 AM

Chairs: M. Martelli, C. Visco, P.L. Zinzani

07
Session

09.45 - 10.00

**Management and Novel Treatment
Approaches in MCL**

C. Visco

10.00 - 10.15

**How I manage primary mediastinal
lymphoma**

M. Martelli

10.15 - 10.30

New Pathways and New Targets in PTCL

P.L. Zinzani

10.30 - 10.45

Primary CNS Lymphoma

A. Ferreri

10.45 - 11.00 Coffee Break



Hodgkin Lymphoma, Non Hodgkin Indolent Lymphomas and Waldenstrom Disease Clinical Session

Ita 11.00 - 12.20 Tx 04.00 - 05.20 AM

Chairs: C. Carlo-Stella, A. Pinto

08
Session

11.00 - 11.15

Microenvironment-driven metabolic rewiring in Lymphomas

A. Romano

11.15 - 11.30

Management Hodgkin frontline Lymphoma in Europe

A. Pinto

11.30 - 11.45

How I manage relapsed/refractory Hodgkin Lymphoma in Europe

C. Carlo-Stella

11.45 - 12.05

How I treat marginal zone and follicular Lymphoma: present and near future

S. Luminari

12.05 - 12.20

Novel opportunities in management of Waldenstrom Disease in Europe

A. Tedeschi

Chronic Lymphocytic Leukemia Clinical Session

Ita 12.20 - 13.20 Tx 05.30 - 06.20 AM

Chairs: A. Cuneo, P. Ghia

09
Session

12.20 - 12.35

How I treat CLL: State of the Art in Italy

A. Cuneo

12.35 - 12.50

Management of relapsed/refractory disease: Novel agents

P. Ghia

12.50 - 13.05

Role of MRD in CLL

M. Massaia

13.05 - 13.20

Biology and management of Richter syndrome

G. Gaidano

13.20 - 13.50 Lunch Time

Lymphomas and Chronic Lymphocytic Leukemia Symposium

Ita 13.50 - 15.20 Tx 06.50 - 08.20 AM



Extra

CME SESSION

Chairs: A. Cashen, N. Fowler, G. Musuraca, S. P. Treon

13.50 - 14.05

How I manage DLBCL in USA

N. Fowler

14.05 - 14.20

Management of indolent lymphomas in 2021

N. Fowler

14.20 - 14.35

How I manage Hodgkin Disease in USA

A. Cashen

14.35 - 14.50

How I manage Waldenstrom's macroglobulinemia

S. P. Treon

Chairs: A. Ferrajoli, A. Paulus

14.50 - 15.05

How I treat CLL: State of the Art in USA

A. Ferrajoli

15.05 - 15.20

Targeting CD38 to reshape the tumor immune microenvironment and its clinical impact in CLL

A. Paulus

Chronic Myeloid Leukemia – Clinical Session

Ita 15.20 - 16.35 Tx 08.20 - 09.35 AM

Chairs: G. Rosti, G. Saglio

10
Session

15.20 - 15.35

European Leukemia Net 2013 vs 2020: what's new?

F. Pane

15.35 - 15.50

Asciminib in brief

G. Saglio

15.50 - 16.05

Ponatinib: which dose and when?

G. Rosti

16.05 - 16.20

Treatment free remission or partially treatment free remission

M. Malagola

16.20 - 16.35

Becoming pregnant on TKI: management and expectations in 2021

E. Abruzzese

16.35 - 16.50 Coffee Break



CML and Myeloproliferative Neoplasms Symposium

Ita 16.50 - 18.20 Tx 09.50 - 11.20 AM

Chairs: E. Jabbour, S. Soverini, A. Tefferi, S. Verstovsek



Extra
CME SESSION

16.50 - 17.05

How I manage CML in 2021

E. Jabbour

17.05 - 17.20

Molecular Testing of CML Patients in 2021: digital vs RT-PCR: Between Old and New Tools

S. Soverini

17.20 - 17.35

Blast crisis in 2021: TKI or chemotherapy bridging to alloSCT?

F. Castagnetti

17.35 - 17.50

Myelofibrosis in 2021: updates on risk stratification and management

A. Tefferi

17.50 - 18.05

Prognostication and Therapy of Essential Thrombocythemia (ET)

A. Tefferi

18.05 - 18.20

Potential New Therapeutic Approaches for Myelofibrosis

S. Verstovsek

Acute Lymphoblastic Leukemia Symposium

Ita 18.20 - 20.05 Tx 11.20 - 01.05 PM

Chairs: C. Cerchione, E. Jabbour, H. Kantarjian, M. Konopleva, G. Martinelli



Extra
CME SESSION

18.20 - 18.35

The MDACC vision of research and therapy in ALL in 2021

H. Kantarjian

18.35 - 18.50

Elderly treatment in ALL - Hyper CVAD in 2021: Lessons Learned and New Approaches

E. Jabbour

18.50 - 19.05

Management of Ph positive ALL

E. Jabbour

19.05 - 19.20

Ph-like and new genetic subtypes and treatment implications

M. Konopleva

19.20 - 19.35

Asparaginase: Understanding and Overcoming Toxicities

C. Papayannidis

19.35 - 19.50

Role of BCL-2 family proteins in ALL survival and chemoresistance

M. Konopleva

19.50 - 20.05

Novel Options in ALL

G. Martinelli

Closing remarks Day 2

Ita 20.05 Tx 01.05 PM

Chairs: C. Cerchione
G. Martinelli





Day 3

30

09.21



Selected Oral Presentations

Ita 08.30 - 09.30 Tx 01.30 - 02.30 AM

12
Session

08.30 - 08.40

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

G. Pianigiani

08.40 - 08.50

Rewiring redox homeostasis to overcome resistance of DLBCL cells to ABT-199

F. Ciccarese

08.50 - 09.00

Aspen: results of a phase 3 randomized trial of Zanubrutinib versus Ibrutinib for patients with Waldenström macroglobulinemia

A. Tedeschi

09.00 - 09.10

MicroRNAs as potential diagnostic and therapeutic biomarkers in Acute Myeloid Leukemia

I. Mushtaq

09.10 - 09.20

Triage against COVID 19 (TRAC19): a software to support Triage in hospitals

N. Gentili

09.20 - 09.30

Panel Discussion

Multiple Myeloma - Biology

Ita 09.30 - 11.00 Tx 02.30 - 04.00 AM

Chairs: N. Bolli, F. Malavasi, B. Paiva, C. Terragna

13
Session

09.30 - 09.45

New insights into biology of MM, SMM and MGUS

C. Terragna

09.45 - 10.00

Importance of flow cytometry in MM

B. Paiva

10.00 - 10.15

Genetic profiling of Multiple Myeloma in novel agents era

N. Bolli

10.15 - 10.30

Targeting the bone marrow microenvironment in Multiple Myeloma

C. Botta

10.30 - 10.45

New insights in anti-angiogenesis in Multiple Myeloma

A. Solimando

10.45 - 11.00

The intricate world behind the action of the therapeutic anti-CD38 antibodies

F. Malavasi

Multiple Myeloma Clinical Session 1

Ita 11.00 - 12.30 Tx 04.00 - 05.30 AM

Chairs: M.T. Petrucci, E. Zamagni

14
Session

11.00 - 11.15

Newly diagnosed transplant-eligible MM

V. Montefusco

11.15 - 11.30

Unfit/frail patients

D. Derudas

11.30 - 11.45

Role of autologous in current era of MM

M.T. Petrucci

11.45 - 12.00

Drug resistance in Multiple Myeloma

M. Bebawy

12.00 - 12.15

Important of imaging in novel agents'era in MM

E. Zamagni

12.15 - 12.30

Role of PET/CT + Whole Body MRI in the management of MM

F. Matteucci, A. Rossi

Multiple Myeloma Clinical Session 2

Ita 12.30 - 13.45 Tx 05.30 - 07.30 AM

Chairs: M. Martino, F. Di Raimondo

15
Session

12.30 - 12.45

CAR-T and ASCT in MM

M. Martino

12.45 - 13.00

Dissecting Daratumumab mechanisms of resistance at a single-cell level

M. Da Vià

13.00 - 13.15

Importance of Quality of life in MM

P. Tosi

13.15 - 13.30

New drugs on the Horizon in Europe

F. Di Raimondo

13.30 - 13.45

EMN Trials in MM

R. Mina

13.45 - 14.05 Lunch Time



ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

Lunch Symposium: Health Management System

Ita 14.05 - 15.35 Tx 07.05- 08.35 AM

Chairs: P. Burioli, G. Martinelli, M.T. Montella



14.05 - 14.15

Management model of Italian oncohematology research Institution

M.T. Montella

14.15 - 14.25

Role of Oncology registries in Italy: past, present and future

E. Crocetti

14.25 - 14.35

Innovative adaptive trial design: advantages and disadvantages

O. Nanni

14.35 - 14.45

Multidisciplinary approach in IRST: OncoHematology Department

G.L. Frassinetti

14.45 - 14.55

Drug Management in Italy: near future of Oncopharmacist

C. Masini

14.55 - 15.05

Triage Against Covid19 (TRAC19): a platform to support triage in hospitals

A. Pagliarani

15.05 - 15.15

Oncology Department in Tanzania (in memory of Prof Dino Amadori)

P. Serra

15.15 - 15.25

IRST Research office model: looking for Koalas in the forest

A. Volpi

15.25 - 15.35

Road to CCRN Romagna and role of SOHO Italy

G. Martinelli, C. Cerchione

Multiple Myeloma Symposium

Ita 15.35 - 17.20 Tx 08.35 - 10.20 AM

Chairs: K.C. Anderson, H.C. Lee, C. Cerchione, G. Martinelli, M.V. Mateos

15.35 - 15.50

Multiple Myeloma: State of the art in Europe

C. Cerchione

15.50 - 16.05

Multiple Myeloma: State of the art in USA

K.C. Anderson

16.05 - 16.20

Smoldering Multiple Myeloma: State of the art

M.V. Mateos

16.20 - 16.35

Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies

H.C. Lee

16.35 - 16.50

Next Generation Cellular Therapies: NK Cells, AlloCARs, Vaccines, etc

N. Shah

16.50 - 17.05

How I manage AL Amyloidosis in Europe

G. Palladini

17.05 - 17.20

Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis

G. Kaufman

Acute Lymphoblastic Leukemia Clinical Session

Ita 17.20 - 18.50 Tx 10.20 - 11.50 AM

Chairs: S. Chiaretti, G. Martinelli

16
Session

17.20 - 17.35

How I manage Acute Lymphoblastic Leukemia in Europe

G. Martinelli

17.35 - 17.50

Chemotherapy Free Regimens in ALL

S. Chiaretti

17.50 - 18.05

Blinatumumab and Inotuzumab in Europe

C. Papayannidis

18.05 - 18.20

Ph+ ALL: does the host immune system play a role in the control of the disease?

R. Foà

18.20 - 18.35

Infectious complications during Monoclonal Antibodies treatments and Cell therapies in ALL

L. Pagano

18.35 - 18.50

Role of allogeneic transplantation in the era of novel agents

F. Lanza

18.50 - 19.05 Coffee break



Chronic Myeloproliferative Neoplasms, Session on novel targets

Ita 19.05 - 19.50 Tx 00.05 - 00.50 PM

Chairs: C. Fava

17
Session

19.05 - 19.20

Personalized medicine for MPN patients

T. Mughal

19.35 - 19.50

Being a Myeloproliferative Patient in COVID-19 Era: The mytico Study

F. Cavalca

19.20 - 19.35

From platelet fibrinogen receptor to global coagulation assays in MPNs

A. Lucchesi

Prizes and Conclusions. See you next year

Ita 19.50 - 20.05 Tx 00.50 - 01.05 PM

Chairs: C. Cerchione, G. Martinelli





Supported by an unrestricted
educational grant from

abbvie

AstraZeneca 

 astellas

 BeiGene

 blueprint
MEDICINES

Celgene |  Bristol Myers Squibb™
Company


Daiichi-Sankyo

diatech
pharmacogenetics

 gsk

 Incyte

janssen  Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

 Jazz Pharmaceuticals®

 Karyopharm®
Therapeutics

 MEI
pharma

neovii

 NOVARTIS

 Pfizer

 Stemline®
A Menarini Group Company



Follow Us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is **#SOHOItaly21**

You can use it on **Facebook**, **Twitter**, **Instagram** and **Linkedin**. Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly

@SocietyofHemOnc

@IRSTufficiale

@MDAndersonNews

@pro_eventi

@GMartinelli2

@DottorClaudio

@DrHKantarjian

@Daver_Leukemia

@DrNathanFowler

@garciamanero

@TapKadia

Enjoy & Share your experience!

Follow us
#SOHOItaly2021







ISTITUT
ROMAGN
PER LO
DEI TUM
DINI AMADORI

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Unità Sanitaria Locale della Romagna